Madariaga, Ainhoa https://orcid.org/0000-0001-7166-9762
Bowering, Valerie
Ahrari, Soha
Oza, Amit M
Lheureux, Stephanie
Clinical trials referenced in this document:
Documents that mention this clinical trial
Can somatic BRCA2 status solve a case of olaparib monotherapy resistance?
https://doi.org/10.1136/ijgc-2019-000757
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
https://doi.org/10.1136/ijgc-2020-001288
Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review
https://doi.org/10.1136/ijgc-2019-001041
PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis
https://doi.org/10.1016/j.ygyno.2015.08.013
321 Maintenance olaparib for BRCA-mutated ovarian cancer (OC) patients in 1st line and platinum-sensitive relapsed (PSR) settings: maximizing treatment opportunities
https://doi.org/10.1136/ijgc-2019-igcs.321
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment
https://doi.org/10.1136/ijgc-2020-001694
FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited
https://doi.org/10.1016/j.ygyno.2016.06.013
Outcomes and endpoints of relevance in gynecologic cancer clinical trials
https://doi.org/10.1136/ijgc-2022-003727
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study
https://doi.org/10.1016/j.ygyno.2015.03.042
Interviews conducted at the European Society of Gynaecological Oncology 2022 Congress: a ENYGO-IJGC Fellows initiative
https://doi.org/10.1136/ijgc-2022-004160
#512 Real-World utilisation and clinical outcomes of patients with BRCA-mutated advanced ovarian cancer treated with olaparib in the first-line maintenance setting: 2-year clinical outcomes of the pan-European OVAL-1 study
https://doi.org/10.1136/ijgc-2023-esgo.895
Targeting the hallmarks of ovarian cancer: The big picture
https://doi.org/10.1016/j.ygyno.2016.03.037
PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials
https://doi.org/10.1016/j.ygyno.2016.05.003
Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis
https://doi.org/10.1136/ijgc-2022-003614
Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know
https://doi.org/10.1016/j.ygyno.2016.01.003
New windows of surgical opportunity for gynecological cancers in the era of targeted therapies
https://doi.org/10.1136/ijgc-2023-004580
392 Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: subgroup analysis by risk in the phase III solo1 study
https://doi.org/10.1136/ijgc-2020-esgo.130
Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883)
https://doi.org/10.1136/jmedgenet-2018-105930
Report from the European Society of Gynaecological Oncology (ESGO) 2020 State-of-the-Art Virtual Meeting
https://doi.org/10.1136/ijgc-2021-002577
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
https://doi.org/10.1200/jco.22.01549
Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the Phase III SOLO1 trial
https://doi.org/10.1136/ijgc-2019-esgo.17
Documents that mention this clinical trial
22nd meeting of the European Society of Gynaecological Oncology (ESGO 2021) report
https://doi.org/10.1136/ijgc-2022-003593
347 Efficacy and safety of niraparib in older patients (PTS) with advanced ovarian cancer (OC): results from the prima/ENGOT-OV26/GOG-3012 trial
https://doi.org/10.1136/ijgc-2020-esgo.123
Safety and management of niraparib monotherapy in ovarian cancer clinical trials
https://doi.org/10.1136/ijgc-2022-004079
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
https://doi.org/10.1136/ijgc-2020-001288
Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer
https://doi.org/10.1136/ijgc-2018-000071
177 Efficacy of niraparib by timing of surgery and residual disease: a post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
https://doi.org/10.1136/ijgc-2021-esgo.349
Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
https://doi.org/10.1136/ijgc-2019-000499
13 Efficacy on individualized starting dose (ISD) and fixed starting dose (FSD) of niraparib per investigator-assessment (IA) in newly diagnosed advanced ovarian cancer (OC)
https://doi.org/10.1136/ijgc-2020-igcs.13
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment
https://doi.org/10.1136/ijgc-2020-001694
388 Efficacy of individualised starting dose (ISD) and fixed starting dose (FSD) of niraparib per investigator assessment (IA) in newly diagnosed advanced ovarian cancer (OC) patients
https://doi.org/10.1136/ijgc-2020-esgo.154
Outcomes and endpoints of relevance in gynecologic cancer clinical trials
https://doi.org/10.1136/ijgc-2022-003727
17 Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial
https://doi.org/10.1136/ijgc-2020-igcs.17
Interviews conducted at the European Society of Gynaecological Oncology 2022 Congress: a ENYGO-IJGC Fellows initiative
https://doi.org/10.1136/ijgc-2022-004160
961 Impact of disease progression on health-related quality of life of advanced ovarian cancer (AOC) patients – pooled analysis from the PRIMA trial
https://doi.org/10.1136/ijgc-2021-esgo.494
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study
https://doi.org/10.1136/ijgc-2024-005356
Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis
https://doi.org/10.1136/ijgc-2022-003614
#556 Tolerability of the niraparib individualised starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy
https://doi.org/10.1136/ijgc-2024-esgo.1128
New windows of surgical opportunity for gynecological cancers in the era of targeted therapies
https://doi.org/10.1136/ijgc-2023-004580
Predictors of long-term progression-free survival (PFS) in niraparib-treated patients (pts) from the PRIMA/ENGOT-OV26/GOG-3012 study.
https://doi.org/10.1200/jco.2023.41.16_suppl.5589
2022-RA-949-ESGO VOCAL (views of ovarian cancer patients-how maintenance therapy affects their lives) study: patient preference for treatment formulation and administration
https://doi.org/10.1136/ijgc-2022-esgo.602
EP233/#541 Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease following first-line chemotherapy: PRIMA/ENGOT-ov26/GOG-3012 post-hoc subgroup analysis
https://doi.org/10.1136/ijgc-2022-igcs.324
294 Patient-reported outcomes (PROS) in patients (PTS) receiving niraparib in the prima/engot-ov26/gog-3012 trial
https://doi.org/10.1136/ijgc-2020-esgo.114
Treatment of epithelial ovarian cancer
https://doi.org/10.1136/bmj.m3773
EP301/#854 VOCAL (views of ovarian cancer patients-how maintenance therapy affects their lives) study: patient preference for treatment formulation and administration
https://doi.org/10.1136/ijgc-2022-igcs.392
Documents that mention this clinical trial
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
https://doi.org/10.1136/ijgc-2020-001288
Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review
https://doi.org/10.1136/ijgc-2019-001041
Targeting the hallmarks of ovarian cancer: The big picture
https://doi.org/10.1016/j.ygyno.2016.03.037
Pathologic response to neoadjuvant chemotherapy in advanced ovarian cancer: utility of a scoring system to predict outcomes
https://doi.org/10.1136/ijgc-2019-000232
Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis
https://doi.org/10.1136/ijgc-2022-003614
16 Quality-adjusted (QA) progression-free survival analyses of veliparib + carboplatin/paclitaxel (CP) vs CP alone in patients with newly diagnosed ovarian cancer
https://doi.org/10.1136/ijgc-2020-igcs.16
New windows of surgical opportunity for gynecological cancers in the era of targeted therapies
https://doi.org/10.1136/ijgc-2023-004580
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma
https://doi.org/10.1016/j.ygyno.2016.08.328
Treatment of epithelial ovarian cancer
https://doi.org/10.1136/bmj.m3773
Documents that mention this clinical trial
Evolution of evidence on overall survival benefits of cancer drugs included on the national reimbursement drug list of China, 2005–2022: an observational study
https://doi.org/10.1136/bmjebm-2025-113722
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
https://doi.org/10.1136/ijgc-2020-001288
PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy
https://doi.org/10.1136/ijgc-2022-003990
Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review
https://doi.org/10.1136/ijgc-2019-001041
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment
https://doi.org/10.1136/ijgc-2020-001694
Targeted trials in ovarian cancer
https://doi.org/10.1016/j.ygyno.2010.05.008
Interviews conducted at the European Society of Gynaecological Oncology 2022 Congress: a ENYGO-IJGC Fellows initiative
https://doi.org/10.1136/ijgc-2022-004160
Documents that mention this clinical trial
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
https://doi.org/10.1136/ijgc-2020-001288
PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy
https://doi.org/10.1136/ijgc-2022-003990
Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review
https://doi.org/10.1136/ijgc-2019-001041
PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis
https://doi.org/10.1016/j.ygyno.2015.08.013
321 Maintenance olaparib for BRCA-mutated ovarian cancer (OC) patients in 1st line and platinum-sensitive relapsed (PSR) settings: maximizing treatment opportunities
https://doi.org/10.1136/ijgc-2019-igcs.321
The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers
https://doi.org/10.1136/ijgc-2020-001789
Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
https://doi.org/10.1136/ijgc-2019-000499
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment
https://doi.org/10.1136/ijgc-2020-001694
Outcomes and endpoints of relevance in gynecologic cancer clinical trials
https://doi.org/10.1136/ijgc-2022-003727
Efficacy and safety updates of poly ADP-ribose polymerase (PARP) inhibitor maintenance in ovarian cancer from ASCO 2020
https://doi.org/10.1136/ijgc-2020-001723
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study
https://doi.org/10.1016/j.ygyno.2015.03.042
Homologous recombination deficiency and ovarian cancer
https://doi.org/10.1016/j.ejca.2016.03.005
PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials
https://doi.org/10.1016/j.ygyno.2016.05.003
Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis
https://doi.org/10.1136/ijgc-2022-003614
Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know
https://doi.org/10.1016/j.ygyno.2016.01.003
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups
https://doi.org/10.1136/ijgc-2022-003435
Documents that mention this clinical trial
Safety and management of niraparib monotherapy in ovarian cancer clinical trials
https://doi.org/10.1136/ijgc-2022-004079
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
https://doi.org/10.1136/ijgc-2020-001288
PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy
https://doi.org/10.1136/ijgc-2022-003990
Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review
https://doi.org/10.1136/ijgc-2019-001041
The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers
https://doi.org/10.1136/ijgc-2020-001789
Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
https://doi.org/10.1136/ijgc-2019-000499
Outcomes and endpoints of relevance in gynecologic cancer clinical trials
https://doi.org/10.1136/ijgc-2022-003727
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study
https://doi.org/10.1016/j.ygyno.2015.03.042
Homologous recombination deficiency and ovarian cancer
https://doi.org/10.1016/j.ejca.2016.03.005
Best original research presented at the 24th European Congress on Gynaecological Oncology—Best of ESGO 2023
https://doi.org/10.1136/ijgc-2023-005132
PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials
https://doi.org/10.1016/j.ygyno.2016.05.003
Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis
https://doi.org/10.1136/ijgc-2022-003614
Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know
https://doi.org/10.1016/j.ygyno.2016.01.003
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma
https://doi.org/10.1016/j.ygyno.2016.08.328
Documents that mention this clinical trial
Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age
https://doi.org/10.1136/ijgc-2019-esgo.29
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
https://doi.org/10.1136/ijgc-2020-001288
Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review
https://doi.org/10.1136/ijgc-2019-001041
O016/#233 Clinical and molecular characteristics of ariel3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC)
https://doi.org/10.1136/ijgc-2021-igcs.16
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3
https://doi.org/10.1136/ijgc-2020-002240
The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers
https://doi.org/10.1136/ijgc-2020-001789
Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
https://doi.org/10.1136/ijgc-2019-000499
Outcomes and endpoints of relevance in gynecologic cancer clinical trials
https://doi.org/10.1136/ijgc-2022-003727
Health-related quality of life outcomes reporting associated with FDA approvals in haematology and oncology
https://doi.org/10.1136/bmjonc-2024-000369
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study
https://doi.org/10.1016/j.ygyno.2015.03.042
Targeting the hallmarks of ovarian cancer: The big picture
https://doi.org/10.1016/j.ygyno.2016.03.037
Homologous recombination deficiency and ovarian cancer
https://doi.org/10.1016/j.ejca.2016.03.005
O003/#557 Overall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma
https://doi.org/10.1136/ijgc-2022-igcs.5
3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations
https://doi.org/10.1136/ijgc-2020-igcs.3
PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials
https://doi.org/10.1016/j.ygyno.2016.05.003
1 Analysis of patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer in the phase 3 ARIEL3 study
https://doi.org/10.1136/ijgc-2021-esgo.331
Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis
https://doi.org/10.1136/ijgc-2022-003614
Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know
https://doi.org/10.1016/j.ygyno.2016.01.003
2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma
https://doi.org/10.1136/ijgc-2022-esgo.488
Documents that mention this clinical trial
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
https://doi.org/10.1136/ijgc-2020-001288
Documents that mention this clinical trial
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
https://doi.org/10.1136/ijgc-2020-001288
Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review
https://doi.org/10.1136/ijgc-2019-001041
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer
https://doi.org/10.1136/ijgc-2018-000071
Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance.
https://doi.org/10.1200/jco.2023.41.16_suppl.5550
Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
https://doi.org/10.1136/ijgc-2019-000499
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment
https://doi.org/10.1136/ijgc-2020-001694
FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited
https://doi.org/10.1016/j.ygyno.2016.06.013
Outcomes and endpoints of relevance in gynecologic cancer clinical trials
https://doi.org/10.1136/ijgc-2022-003727
Interviews conducted at the European Society of Gynaecological Oncology 2022 Congress: a ENYGO-IJGC Fellows initiative
https://doi.org/10.1136/ijgc-2022-004160
Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study
https://doi.org/10.1136/ijgc-2019-000512
Targeting the hallmarks of ovarian cancer: The big picture
https://doi.org/10.1016/j.ygyno.2016.03.037
Best original research presented at the 24th European Congress on Gynaecological Oncology—Best of ESGO 2023
https://doi.org/10.1136/ijgc-2023-005132
167 Safety and quality of life of first-line maintenance olaparib plus bevacizumab in older patients with advanced ovarian cancer in the PAOLA-1 trial
https://doi.org/10.1136/ijgc-2021-esgo.346
Pathologic response to neoadjuvant chemotherapy in advanced ovarian cancer: utility of a scoring system to predict outcomes
https://doi.org/10.1136/ijgc-2019-000232
Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis
https://doi.org/10.1136/ijgc-2022-003614
Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab
https://doi.org/10.1136/ijgc-2019-esgo.10
#528 Efficacy of subsequent chemotherapy followed by PARP inhibitor maintenance in patients with advanced ovarian cancer in the phase III PAOLA-1/ENGOT-Ov25 trial
https://doi.org/10.1136/ijgc-2023-esgo.30
18 Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial
https://doi.org/10.1136/ijgc-2020-igcs.18
New windows of surgical opportunity for gynecological cancers in the era of targeted therapies
https://doi.org/10.1136/ijgc-2023-004580
Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial
https://doi.org/10.1200/po.22.00258
2022-RA-935-ESGO Development of an academic genomic instability score for ovarian cancers
https://doi.org/10.1136/ijgc-2022-esgo.596
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
https://doi.org/10.1136/ijgc-2023-004995
<i>BRCA1</i> and <i>RAD51</i> methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study.
https://doi.org/10.1200/jco.2023.41.16_suppl.5559
Documents that mention this clinical trial
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
https://doi.org/10.1136/ijgc-2020-001288
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
https://doi.org/10.1136/esmoopen-2020-001110
Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.
https://doi.org/10.1200/jco.2023.41.17_suppl.lba5506
Neoadjuvant immunotherapy of locoregionally advanced solid tumors
https://doi.org/10.1136/jitc-2022-005036
Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study
https://doi.org/10.1136/ijgc-2019-000512
Best original research presented at the 24th European Congress on Gynaecological Oncology—Best of ESGO 2023
https://doi.org/10.1136/ijgc-2023-005132
#1120 Durvalumab with paclitaxel/carboplatin + bevacizumab then maintenance durvalumab, bevacizumab + olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour BRCA1/2 mutation: results from the DUO-O/ENGOT-Ov46/AGO-OVAR 23/GOG-3025 trial
https://doi.org/10.1136/ijgc-2023-esgo.899
Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8<sup>+</sup> TILs based on <i>BRCA1/2</i> mutation status in epithelial ovarian cancers
https://doi.org/10.1136/jitc-2024-009058
Treatment of epithelial ovarian cancer
https://doi.org/10.1136/bmj.m3773
Documents that mention this clinical trial
Advanced Clinical Trials of Dendritic Cell Vaccines in Ovarian Cancer
https://doi.org/10.1136/jim-2020-001355
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
https://doi.org/10.1136/ijgc-2020-001288
P116 ATHENA (GOG-3020/ENGOT-ov45; EudraCT 2017–004557–17; NCT03522246): a randomised, double-blind, placebo-controlled, phase 3 study of the poly(ADP-Ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer (OC)
https://doi.org/10.1136/ijgc-2019-esgo.179
Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
https://doi.org/10.1136/ijgc-2019-000499
Outcomes and endpoints of relevance in gynecologic cancer clinical trials
https://doi.org/10.1136/ijgc-2022-003727
First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
https://doi.org/10.1136/esmoopen-2020-001110
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
https://doi.org/10.1136/ijgc-2021-002933
Interviews conducted at the European Society of Gynaecological Oncology 2022 Congress: a ENYGO-IJGC Fellows initiative
https://doi.org/10.1136/ijgc-2022-004160
176 Rucaparib maintenance treatment in patients (Pts) with newly diagnosed ovarian cancer (OC): defining benefit according to disease risk subgroups within the phase 3 ATHENA-MONO study
https://doi.org/10.1136/ijgc-2024-esgo.584
Final safety results from ATHENA–MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer.
https://doi.org/10.1200/jco.2024.42.16_suppl.5554
2022-LBA-325-ESGO Patients with newly diagnosed ovarian cancer treated with maintenance rucaparib: exploratory biomarker analysis from the phase 3 ATHENA-MONO study (GOG-3020/ENGOT-ov45; NCT03522246)
https://doi.org/10.1136/ijgc-2022-esgo.1018
Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8<sup>+</sup> TILs based on <i>BRCA1/2</i> mutation status in epithelial ovarian cancers
https://doi.org/10.1136/jitc-2024-009058
New windows of surgical opportunity for gynecological cancers in the era of targeted therapies
https://doi.org/10.1136/ijgc-2023-004580
O026/#560 Efficacy analysis by disease risk subgroup for the phase 3 athena-mono study (GOG-3020/engot-OV45) evaluating rucaparib maintenance treatment in patients with newly diagnosed ovarian cancer
https://doi.org/10.1136/ijgc-2022-igcs.28
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
https://doi.org/10.1200/jco.22.01003
Documents that mention this clinical trial
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
https://doi.org/10.1136/ijgc-2020-001288
Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions
https://doi.org/10.1136/ijgc-2022-004149
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
https://doi.org/10.1136/ijgc-2021-002593
Systemic therapy de-escalation in advanced ovarian cancer: a new era on the horizon?
https://doi.org/10.1136/ijgc-2023-004740
Documents that mention this clinical trial
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
https://doi.org/10.1136/ijgc-2020-001288
PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy
https://doi.org/10.1136/ijgc-2022-003990
Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review
https://doi.org/10.1136/ijgc-2019-001041
The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers
https://doi.org/10.1136/ijgc-2020-001789
Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
https://doi.org/10.1136/ijgc-2019-000499
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment
https://doi.org/10.1136/ijgc-2020-001694
First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
https://doi.org/10.1136/esmoopen-2020-001110
2022-RA-1290-ESGO Maintenance olaparib rechallenge in patients with ovarian cancer previously treated with a PARP inhibitor: detailed safety results from the Phase IIIb OReO/ENGOT-ov38 trial
https://doi.org/10.1136/ijgc-2022-esgo.679
O025/#522 Maintenance olaparib rechallenge in patients with ovarian cancer previously treated with a parp inhibitor: patient-reported outcomes from the phase IIIB OReO/engot-ov38 trial
https://doi.org/10.1136/ijgc-2022-igcs.27
#528 Efficacy of subsequent chemotherapy followed by PARP inhibitor maintenance in patients with advanced ovarian cancer in the phase III PAOLA-1/ENGOT-Ov25 trial
https://doi.org/10.1136/ijgc-2023-esgo.30
Treatment of epithelial ovarian cancer
https://doi.org/10.1136/bmj.m3773
Documents that mention this clinical trial
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
https://doi.org/10.1136/ijgc-2020-001288
Potentiation of cancer immunogenicity by targeting PARP
https://doi.org/10.1136/jitc-2024-011056
The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers
https://doi.org/10.1136/ijgc-2020-001789
Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
https://doi.org/10.1136/ijgc-2019-000499
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment
https://doi.org/10.1136/ijgc-2020-001694
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
Management of recurrent ovarian cancer: when platinum-based regimens are not a therapeutic option
https://doi.org/10.1136/ijgc-2019-000624
92 High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlatives of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer
https://doi.org/10.1136/jitc-2024-sitc2024.0092
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer
https://doi.org/10.1136/jitc-2021-003924
This article is maintained by: Elsevier
Article Title: Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
Journal Title: International Journal of Gynecological Cancer
CrossRef DOI link to publisher maintained version: https://doi.org/10.1136/ijgc-2020-001288
Content Type: article
Copyright: Copyright © 2020 This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.